Edition:
India

Arcturus Therapeutics Ltd (ARCT.OQ)

ARCT.OQ on NASDAQ Stock Exchange Global Market

40.70USD
21 Sep 2020
Change (% chg)

-- (--)
Prev Close
$40.70
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
280,212
52-wk High
$66.16
52-wk Low
$8.51

Latest Key Developments (Source: Significant Developments)

Arcturus Therapeutics Announces Pricing Of $173 Mln Public Offering Of Common Stock
Wednesday, 29 Jul 2020 

July 29 (Reuters) - Arcturus Therapeutics Holdings Inc ::ARCTURUS THERAPEUTICS ANNOUNCES PRICING OF $173.0 MILLION PUBLIC OFFERING OF COMMON STOCK.PUBLIC OFFERING OF 3,264,151 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $53.00 PER SHARE.  Full Article

Arcturus, Duke-Nus Say Singapore Approves Clinical Trials For COVID-19 Vaccine Candidate
Wednesday, 22 Jul 2020 

July 22 (Reuters) - Arcturus Therapeutics , Duke-NUS::SAY CLINICAL TRIALS FOR COVID-19 VACCINE CANDIDATE HAS BEEN APPROVED TO PROCEED BY SINGAPORE REGULATOR.SAY WILL INITIATE HUMAN DOSING OF VACCINE CANDIDATE AS SOON AS POSSIBLE.SAY STUDY WILL EVALUATE SEVERAL DOSE LEVELS OF VACCINE CANDIDATE IN UP TO 108 ADULTS, INCLUDING OLDER ADULTS.  Full Article

Arcturus Therapeutics Posts Q1 Loss Per Share of $0.68
Monday, 13 May 2019 

May 13 (Reuters) - Arcturus Therapeutics Ltd ::ARCTURUS THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE.Q1 LOSS PER SHARE $0.68.Q1 EARNINGS PER SHARE ESTIMATE $-0.58 -- REFINITIV IBES DATA.REMAINS ON TRACK TO REDOMICILE FROM AN ISRAELI LIMITED COMPANY TO A DELAWARE CORPORATION.QTRLY COLLABORATION REVENUE WAS $4.4 MILLION VERSUS $2.4 MILLION.Q1 REVENUE VIEW $3.1 MILLION -- REFINITIV IBES DATA.  Full Article

Arcturus Therapeutics Reassumes Full Worldwide Rights To Arct-810, A Clinical Development Candidate For Ornithine Transcarbamylase Deficiency
Monday, 11 Feb 2019 

Feb 11 (Reuters) - Arcturus Therapeutics Ltd ::ARCTURUS THERAPEUTICS REASSUMES FULL WORLDWIDE RIGHTS TO ARCT-810, A CLINICAL DEVELOPMENT CANDIDATE FOR ORNITHINE TRANSCARBAMYLASE (OTC) DEFICIENCY.ARCTURUS THERAPEUTICS LTD - CUREVAC ELECTED NOT TO CONTINUE ITS OBLIGATIONS FOR PRECLINICAL DEVELOPMENT OF ARCT-810.ARCTURUS THERAPEUTICS LTD - ARCT-810 WAS PREVIOUSLY SUBJECT TO A 50/50 COLLABORATION BETWEEN ARCTURUS AND CUREVAC AG.ARCTURUS THERAPEUTICS LTD - PRECLINICAL DEVELOPMENT PROGRAM FOR ARCT-810 INCLUDING IND ENABLING STUDIES, REMAINS ON TRACK.ARCTURUS THERAPEUTICS LTD - PLANNING TO FILE AN IND FOR ARCT-810 WITH U.S. FOOD AND DRUG ADMINISTRATION IN Q4 OF 2019.  Full Article

Arcturus Therapeutics Q3 Loss Per Share $0.42
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Arcturus Therapeutics Ltd ::ARCTURUS THERAPEUTICS PROVIDES CORPORATE UPDATE AND REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.42.  Full Article

FACTBOX-Dozens of countries host clinical trials of coronavirus vaccine candidates

Aug 28 As the race to develop a safe and effective coronavirus vaccine reaches its final stages, pharmaceutical companies have started conducting large human trials in different countries. Some countries also have signed supply deals with the companies. Below is a summary of clinical studies taking place in different countries and international efforts to tie-up with vaccine makers and nations that are ahead in the race. Country/Region Coronavirus vaccine tr